Kewaunee Scientific Corporation, together with its subsidiaries, designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products in the United States and internationally. It operates through two segments, Lab Products Group (LPG) and International. The company offers steel and wood casework and laboratory cabinetry, fume hoods, adaptable modular and flexible systems, movable workstations, stand-alone and work benches, computer enclosures, biological safety cabinets, CO2 incubators, ultralow freezers, epoxy resin work surfaces and sinks, and other laboratory products. It also provides facility design, detailed engineering, construction, and project management services. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and healthcare markets; and its technical products are used in facilities manufacturing computers and light electronics, and by users of computer and networking furniture. It sells its products through dealers, its subsidiaries, and a national stocking distributor. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.…
Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.
Kewaunee Scientific (NASDAQ: KEQU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Furnishings, Fixtures & Appliances industry, part of the Consumer Cyclical sector, and reports about 1,231 employees.
The shares were at 33.55 USD on 20 November 2026, down 19.7% over 52 weeks. Its 52-week range is 32.00 USD to 43.36 USD: the price is 22.6% below the high and 4.8% above the low.
At a market capitalisation of 97.14M USD, it trades at 12.2 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 15 largest Furnishings, Fixtures & Appliances peers is 19.3, a discount of 37% for KEQU.
Kewaunee Scientific reports return on equity of 12.9%, an operating margin of 5.4% and revenue down 6.7% year over year.
Its debt exceeds its cash by 47.23M USD, a debt-to-equity ratio of 0.40. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.